MINNEAPOLIS, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended September 30, 2024. As previously announced, management is hosting an earnings call today at 4:30 p.m. ET. Q3 2024 and Recent Highlights: Up to $12.0 million financing commitment secured from strategic investor, Nan ...

MINNEAPOLIS, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended June 30, 2024. As previously announced, management is hosting an earnings call today at 4:30 p.m. ET. Q2 2024 and Recent Highlights: Clinical Phase 3 ASPIRE clinical trial received favorable third independent safety ...

MINNEAPOLIS, July 30, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), ("Panbela"), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on Aug 13, 2024, at 4:30 PM Eastern Time to discuss results for its second quarter ended June 30, 2024. Conference Call Replay Information The pipeline consists of assets currently in clinical trials with an initial focus on familial a ...

Core Insights - Panbela Therapeutics announced the completion of the third safety review by the Data Safety Monitoring Board (DSMB) for the Phase 3 ASPIRE trial, recommending continuation without modification, which is the third consecutive positive review [1][11] - The ASPIRE trial evaluates ivospemin in combination with gemcitabine and nab-Paclitaxel for treating metastatic pancreatic ductal adenocarcinoma (mPDAC), a condition with a median overall survival of less than 12 months [2][3] - The safety database now includes 395 patients, an increase from 214 patients as of November 29, 2023, indicating robust data for evaluating ivospemin's safety [1][11] Industry Context - Recent advancements in mPDAC treatment, such as the Napoli 3 trial, have led to the approval of liposomal irinotecan (Onivyde), which provides a median overall survival benefit of 1.9 months compared to gemcitabine and nab-paclitaxel [2] - Despite these advancements, the prognosis for mPDAC patients remains poor, with incremental survival benefits over the past 11 years being modest [2] - The ASPIRE trial is positioned to potentially improve outcomes for mPDAC patients, with an interim survival analysis expected in early 2025 [3][12] Pipeline Overview - Panbela's pipeline includes assets in clinical trials focusing on familial adenomatous polyposis (FAP), first-line metastatic pancreatic cancer, neoadjuvant pancreatic cancer, colorectal cancer prevention, and ovarian cancer [4] - Ivospemin (SBP-101) is designed to inhibit polyamine metabolism, showing a median overall survival of 14.6 months and an objective response rate of 48% in clinical studies, which exceeds the standard of care [5] - Flynpovi, a combination therapy, has demonstrated significant benefits in preventing pre-cancerous adenomas in patients with sporadic large bowel polyps [6]

DSMB Recommends Continuation without Modification for Third Time Safety Review Included 395 Patients Interim Survival Analysis Still Expected Early 2025 given Lower-Than-Expected Event Rate Low Event Rate Suggests Potential for Prolonged Survival Rapid Enrollment Positions Company for Enrollment Completion by Q1 2025; Earlier Than Expected MINNEAPOLIS, June 24, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No.: 001-39468 Panbela Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 88-2805017 (State or other juri ...

Q1 2024 and recent Highlights: Clinical Exhibit 99.1 Panbela Provides Business Update and Reports Q1 2024 Financial Results MINNEAPOLIS, May 15, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended March 31, 2024. As previously announced, management is hosting earnings call today at 4:30 p ...

MINNEAPOLIS, May 15, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended March 31, 2024. As previously announced, management is hosting earnings call today at 4:30 p.m. ET. "We were thrilled to announce that our ongoing ASPIRE trial, evaluating ivospemin (SBP-101) in combination with stand ...

Panbela Therapeutics, Inc. (OTC:PBLA) Q4 2023 Earnings Conference Call March 26, 2024 4:30 PM ET Company Participants James Carbonara - Investor Relations Jennifer Simpson - Chief Executive Officer Sue Horvath - Chief Financial Officer Conference Call Participants Jonathan Aschoff - ROTH MKM Josh Korsen - H.C. Wainwright Operator Greetings. Welcome to Panbela Therapeutics Fourth Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow th ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39468 PANBELA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) ...